Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 7/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31287961 | 1.00 | TSHR (0.60) | TSHRNOTUMAREGLN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL28181337 | 0.98 | TSHR (0.58) | TSHRNOTUMAREGLN2CYP1A2 | |
| SCHEMBL1533157 | 0.83 | TSHR (0.46) | TSHRNOTUMEGLN2CYP1A2CYP2C19 | |
| SCHEMBL410450 | 0.79 | TSHR (0.44) | TSHRNOTUMAREGLN2ALDH1A1 | |
| SCHEMBL1145126 | 0.77 | TSHR (0.38) | TSHRCYP1A2ACHECA1CA2 | |
| SCHEMBL16952678 | 0.77 | TSHR (0.38) | TSHRCYP1A2ACHECA1CA2 | |
| SCHEMBL16959874 | 0.77 | TSHR (0.38) | TSHRCYP1A2ACHECA1CA2 | |
| SCHEMBL15440917 | 0.77 | KIF11 (0.39) | TSHRCYP1A2ACHECA1CA2 | |
| SCHEMBL21022697 | 0.76 | TSHR (0.65) | TSHRNOTUMARCYP1A2CYP2C19 | |
| SCHEMBL30443847 | 0.76 | BCAT1 (0.49) | TSHRNOTUMEGLN2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105492433-B | 6- (5-hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as PHD inhibitors | 武田药品工业株式会社 | 2018-11-23 | — | — | CN | claimed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| CN-120136870-A | GLP-1 receptor targeting compounds and uses thereof | 信达生物科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| WO-2025119206-A1 | GLP-1 RECEPTOR TARGETING COMPOUNDS AND USES THEREOF | FORTVITA BIOLOGICS INC. (KY) | 2025-06-12 | — | — | WO | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| CN-118715221-A | Tricyclic compounds and uses thereof | 希格生科（深圳）有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| WO-2024073624-A2 | ANTIPROLIFERATIVE BETTI BASES AND PRODRUGS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2010015518-A2 | 4-DIMETHYLAMINO-PHENYL-SUBSTITUTED NAPHTHYRIDINES, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNTIONAL GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | disclosed |
| WO-2007026916-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | TSHR 241/4885NOTUM 460/4885AR 3860/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | TSHR 4633/4885NOTUM 242/4885AR 3827/4885 |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | HRH2, ASNS, GHSR | TSHR 343/4885NOTUM 268/4885AR 3663/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | TSHR 34/4885NOTUM 2294/4885AR 4452/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | TSHR 2837/4885NOTUM 276/4885AR 1062/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | TSHR 344/4885NOTUM 3681/4885AR 3055/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | TSHR 344/4885NOTUM 3681/4885AR 3055/4885 |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | TSHR 2323/4885NOTUM 3419/4885AR 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.